Patents by Inventor Cornelis Joseph Maria Melief

Cornelis Joseph Maria Melief has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthetic long peptides (SLP) for therapeutic vaccination against Hepatitis B virus infection
    Patent number: 10898567
    Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel peptides that may be used in the treatment and/or prevention of a Hepatitis B viral infection and/or an Hepatitis B related disease or condition.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: January 26, 2021
    Assignee: ISA PHARMACEUTICALS B.V.
    Inventors: Wilhelmus Johannes Theodorus Alexander Krebber, Johan Herman Kessler, Cornelis Joseph Maria Melief, Kitty Michelle Corinne Kwappenberg
  • SYNTHETIC LONG PEPTIDES (SLP) FOR THERAPEUTIC VACCINATION AGAINST HEPATITIS B VIRUS INFECTION
    Publication number: 20190314494
    Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel peptides that may be used in the treatment and/or prevention of a Hepatitis B viral infection and/or an Hepatitis B related disease or condition.
    Type: Application
    Filed: July 1, 2019
    Publication date: October 17, 2019
    Applicant: ISA Pharmaceuticals B.V.
    Inventors: Wilhelmus Johannes Theodorus Alexander KREBBER, Johan Herman KESSLER, Cornelis Joseph Maria MELIEF, Kitty Michelle Corinne KWAPPENBERG
  • Synthetic long peptides (SLP) for therapeutic vaccination against hepatitis B virus infection
    Patent number: 10376576
    Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel peptides that may be used in the treatment and/or prevention of a Hepatitis B viral infection and/or an Hepatitis B related disease or condition.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: August 13, 2019
    Assignee: ISA Pharmaceuticals B.V.
    Inventors: Wilhelmus Johannes Theodorus Alexander Krebber, Johan Herman Kessler, Cornelis Joseph Maria Melief, Kitty Michelle Corinne Kwappenberg
  • SYNTHETIC LONG PEPTIDES (SLP) FOR THERAPEUTIC VACCINATION AGAINST HEPATITIS B VIRUS INFECTION
    Publication number: 20170246293
    Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel peptides that may be used in the treatment and/or prevention of a Hepatitis B viral infection and/or an Hepatitis B related disease or condition.
    Type: Application
    Filed: June 1, 2015
    Publication date: August 31, 2017
    Applicant: ISA Pharmaceuticals B.V.
    Inventors: Wilhelmus Johannes Theodorus Alexander KREBBER, Johan Herman KESSLER, Cornelis Joseph Maria MELIEF, Kitty Michelle Corinne KWAPPENBERG
  • Peptides, conjugates and method for increasing immunogenicity of a vaccine
    Patent number: 9522962
    Abstract: The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL (residues 383-390 of SEQ ID NO: 3) for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and therapeutic vaccine and in a further embodiment the invention relates to the treatment or prevention of cancer or an infectious disease.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: December 20, 2016
    Assignees: Academisch Ziekenhuis Leiden h.o.d.n. LUMC, Stichting voor de Technische Wetenschappen
    Inventors: Ferdinand Antonius Ossendorp, Cornelis Joseph Maria Melief, Jan Wouter Drijfhout
  • Monophenols and benzenediols sensitization of immune system against haptenized melanoma antigens
    Patent number: 9393219
    Abstract: The metabolization of certain phenols, monophenols or benzenediols into reactive quinone compounds, in particular ortho-quinones and related reactive intermediates, which is brought about by oxidation of monophenols and benzenediols by proteins exhibiting tyrosinase activity, such as human tyrosinase and the related proteins TRP1 and TRP2. The compounds function as haptens that become covalently bound to the tyrosinase enzymes, in particular to histidine moieties, in or near the catalytic site of proteins exhibiting tyrosinase activity, such as tyrosinase, TRP1 and TRP2. An immune response is then to be mounted against these haptenized auto-antigens to treat malignancies.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: July 19, 2016
    Assignees: ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM, ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC
    Inventors: Wiete Westerhof, Cornelis Joseph Maria Melief, Rosalie Margaretha Luiten
  • PEPTIDES, CONJUGATES AND METHOD FOR INCREASING IMMUNOGENICITY OF A VACCINE
    Publication number: 20130071428
    Abstract: The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and therapeutic vaccine and in a further embodiment the invention relates to the treatment or prevention of cancer or an infectious disease.
    Type: Application
    Filed: March 15, 2011
    Publication date: March 21, 2013
    Applicants: STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN, ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC
    Inventors: Ferdinand Antonius Ossendorp, Cornelis Joseph Maria Melief, Jan Wouter Drijfhout
  • SENSITIZATION OF IMMUNE SYSTEM AGAINST HAPTENIZED MELANOMA ANTIGENS
    Publication number: 20120315304
    Abstract: The metabolization of certain phenols, monophenols or benzenediols into reactive quinone compounds, in particular ortho-quinones and related reactive intermediates, which is brought about by oxidation of monophenols and benzenediols by proteins exhibiting tyrosinase activity, such as human tyrosinase and the related proteins TRP1 and TRP2. The compounds function as haptens that become covalently bound to the tyrosinase enzymes, in particular to histidine moieties, in or near the catalytic site of proteins exhibiting tyrosinase activity, such as tyrosinase, TRP1 and TRP2. An immune response is then to be mounted against these haptenized auto-antigens to treat malignancies.
    Type: Application
    Filed: June 11, 2012
    Publication date: December 13, 2012
    Applicants: ACADEMISCH ZIEKENHUIS LEIDEN, ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM
    Inventors: Wiete WESTERHOF, Cornelis Joseph Maria MELIEF, Rosalie Margaretha LUITEN
  • DELIVERY OF A CD40 AGONIST TO A TUMOR DRAINING LYMPH NODE OF A SUBJECT
    Publication number: 20110311525
    Abstract: The invention relates to the use of a CD40 agonist for treating cancer, a pre-malignant disorder or an infectious disease, wherein a CD40 agonist is locally administered and targeted to a tumor draining lymph node of a subject. Optionally, a CD40 agonist is formulated in a slow-release formulation. Optionally, a CTL-activating peptide is further administered.
    Type: Application
    Filed: August 31, 2009
    Publication date: December 22, 2011
    Applicant: ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC
    Inventors: Marieke Fernande Herbert-Fransen, Cornelis Joseph Maria Melief
  • Peptides of human Papilloma virus for use in human T cell response inducing compositions
    Patent number: 7364741
    Abstract: A peptide comprising an amino acid sequence derived from a human papilloma virus (HPV) protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex Class I molecule. Its use in prophylactic or therapeutic treatment of cervical carcinoma and other HPV-related diseases.
    Type: Grant
    Filed: May 4, 1993
    Date of Patent: April 29, 2008
    Assignee: Pharmexa Inc.
    Inventors: Wybe Martin Kast, Cornelis Joseph Maria Melief, Alessandro D. Sette, John C. Sidney
  • Peptides of human P53 protein for use in human T cell response inducing compositions, and human P53 protein-specific cytotoxic t-lymphocytes
    Patent number: 5679641
    Abstract: A peptide comprising an amino acid sequence derived from human p53 protein, wherein said amino acid sequence has the ability to bind to a human MHC Class I molecule. Its use in prophylactic or therapeutic treatment of diseases such as human cancers showing p53 protein overexpression, and its use in induction of primary p53-specific T cells that can be used in therapeutic treatment. Its use in diagnostic tests or assays.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: October 21, 1997
    Assignees: Rijksuniversiteit Leiden, Seed Capital Investments, (SCI) B.V.
    Inventors: Cornelis Joseph Maria Melief, Wybe Martin Kast